Related Experiment Video

Updated: Feb 17, 2026

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.4K

Assessment of TANK-binding kinase 1 as a therapeutic target in cancer

Victoria H Cruz1, Rolf A Brekken2,3

  • 1Cancer Biology Graduate Program, Hamon Center for Therapeutic Oncology Research and Department of Surgery, UT Southwestern Medical Center, 6000 Harry Hines Blvd., Dallas, TX, 75390-8593, USA.

Journal of Cell Communication and Signaling
|December 9, 2017
PubMed

Insights

TANK-binding kinase 1 (TBK1) plays a key role in cancer development, influencing cell division, autophagy, and survival. Targeting TBK1 presents a promising therapeutic strategy for various cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • TANK-binding kinase 1 (TBK1) is a serine threonine protein kinase implicated in tumorigenesis.
  • TBK1 is known for its role in innate immunity but also impacts cell division, autophagy, and AKT-pro survival signaling.
  • It has emerged as a synthetic lethal partner and effector of the oncogene RAS.

Purpose of the Study:

  • To summarize newly identified cancer-promoting functions of TBK1.
  • To evaluate the therapeutic potential of targeting TBK1 in cancer treatment.

Main Methods:

  • Literature review of recent studies on TBK1 in cancer.
  • Analysis of TBK1's roles in tumorigenesis and its interaction with oncogenes like RAS.

Main Results:

  • TBK1 contributes to cancer progression through diverse pathways including cell division and survival signaling.
  • Its synthetic lethality with RAS highlights its importance in specific cancer contexts.
  • Emerging evidence supports TBK1 as a viable therapeutic target.

Conclusions:

  • TBK1 is a multifaceted protein kinase with significant roles in promoting cancer.
  • Targeting TBK1 offers a promising avenue for novel cancer therapies.
  • Further research is warranted to fully exploit TBK1 as a therapeutic target.
Keywords:
AutophagyCancer therapeutic targetPancreatic cancerRASTBK1

More Related Videos

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.7K
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K